These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9779719)

  • 1. Apples and oranges: building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials.
    Dawson NA
    J Clin Oncol; 1998 Oct; 16(10):3398-405. PubMed ID: 9779719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.
    Bubley GJ; Carducci M; Dahut W; Dawson N; Daliani D; Eisenberger M; Figg WD; Freidlin B; Halabi S; Hudes G; Hussain M; Kaplan R; Myers C; Oh W; Petrylak DP; Reed E; Roth B; Sartor O; Scher H; Simons J; Sinibaldi V; Small EJ; Smith MR; Trump DL; Wilding G
    J Clin Oncol; 1999 Nov; 17(11):3461-7. PubMed ID: 10550143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
    Scher HI; Halabi S; Tannock I; Morris M; Sternberg CN; Carducci MA; Eisenberger MA; Higano C; Bubley GJ; Dreicer R; Petrylak D; Kantoff P; Basch E; Kelly WK; Figg WD; Small EJ; Beer TM; Wilding G; Martin A; Hussain M;
    J Clin Oncol; 2008 Mar; 26(7):1148-59. PubMed ID: 18309951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate.
    Smith JA; Lange PH; Janknegt RA; Abbou CC; deGery A
    J Urol; 1997 Apr; 157(4):1329-34. PubMed ID: 9120932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
    Xie W; Nakabayashi M; Regan MM; Oh WK
    Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Failing to achieve a nadir prostate-specific antigen after combined androgen blockade: predictive factors.
    Park SC; Rim JS; Choi HY; Kim CS; Hong SJ; Kim WJ; Lee SE; Song JM; Yoon JH
    Int J Urol; 2009 Aug; 16(8):670-5. PubMed ID: 19602007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum PSA half-life as a predictor of survival for hormone-refractory prostate cancer patients: modelization using a standardized set of response criteria.
    Banu E; Banu A; Medioni J; Levy E; Thiounn N; Mejean A; Andrieu JM; Oudard S
    Prostate; 2007 Oct; 67(14):1543-9. PubMed ID: 17705243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The utility of prostate-specific antigen in the management of advanced prostate cancer.
    Crawford ED; Bennett CL; Andriole GL; Garnick MB; Petrylak DP
    BJU Int; 2013 Sep; 112(5):548-60. PubMed ID: 23826876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
    Canil CM; Moore MJ; Winquist E; Baetz T; Pollak M; Chi KN; Berry S; Ernst DS; Douglas L; Brundage M; Fisher B; McKenna A; Seymour L
    J Clin Oncol; 2005 Jan; 23(3):455-60. PubMed ID: 15659491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience.
    Pether M; Goldenberg SL; Bhagirath K; Gleave M
    Can J Urol; 2003 Apr; 10(2):1809-14. PubMed ID: 12773232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.
    Scher HI; Kelly WK
    J Clin Oncol; 1993 Aug; 11(8):1566-72. PubMed ID: 7687666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy.
    Hirano D; Minei S; Kishimoto Y; Yamaguchi K; Hachiya T; Yoshida T; Yoshikawa T; Endoh M; Yamanaka Y; Yamamoto T; Satoh Y; Ishida H; Okada K; Takimoto Y
    Urol Int; 2005; 75(1):43-9. PubMed ID: 16037707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.
    Gleave ME; Goldenberg SL; Jones EC; Bruchovsky N; Sullivan LD
    J Urol; 1996 Jan; 155(1):213-9. PubMed ID: 7490838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals.
    Collette L; Burzykowski T; Carroll KJ; Newling D; Morris T; Schröder FH; ; ;
    J Clin Oncol; 2005 Sep; 23(25):6139-48. PubMed ID: 16135480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer.
    Shulman MJ; Karam JA; Benaim EA
    Urology; 2004 Apr; 63(4):732-6. PubMed ID: 15072890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
    Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
    Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
    Fujii Y; Kawakami S; Masuda H; Kobayashi T; Hyochi N; Kageyama Y; Kihara K
    BJU Int; 2006 Jun; 97(6):1184-9. PubMed ID: 16686709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
    Meulenbeld HJ; van Werkhoven ED; Coenen JL; Creemers GJ; Loosveld OJ; de Jong PC; Ten Tije AJ; Fosså SD; Polee M; Gerritsen W; Dalesio O; de Wit R
    Eur J Cancer; 2012 Nov; 48(16):2993-3000. PubMed ID: 22677260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response criteria in prostatic carcinoma.
    Dawson NA
    Semin Oncol; 1999 Apr; 26(2):174-84. PubMed ID: 10597728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.